NOVACYT S.A. (NCYT) — H1 Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the NOVACYT H1 results investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the Q and A tab situated in the right hand corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company will review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. And for those benefit and for the benefit of those joining us from France, And I'd now like to hand you over to David Ullman, CEO. Good afternoon to you, sir. Good afternoon. Thank you, and good afternoon, everybody, and welcome to the twenty twenty two half year results presentation in which we'll also cover an extensive update on strategy and execution against our strategy. Next slide, please. Please, take the disclaimer, as read. Next slide, please. So as an organization, we are blessed with our capability from our talented team. Our product portfolio, which you'll see in this presentation, is extensive and expanding, and our operational capability from r and d through to scale up manufacturing and international supply, regulatory and beyond. From a vision perspective, we want to reinforce our vision which is clear. We are committed to becoming a leading global clinical diagnostics company in infectious diseases. That is our strength and our legacy, and we continue on that path. From a purpose perspective, we are proud, to have protected many lives during a pandemic, and we will continue to protect lives across multiple settings in infectious disease. Next slide, plea...